Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists and Research Institute
mi
from
Saint Petersburg, FL
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists and Research Institute
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Georgetown University Medical Center
mi
from
Washington,
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Danvers, MA
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Danvers, MA
Click here to add this to my saved trials
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Besancon Cedex,
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Besancon Cedex,
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
A Phase III Randomized Trial Of Paclitaxel And Carboplatin Versus Triplet Or Sequential Doublet Combinations In Patients With Epithelial Ovarian Or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Gynecologic Oncology Group
mi
from
Philadelphia, PA
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
A Phase III Randomized Trial Of Paclitaxel And Carboplatin Versus Triplet Or Sequential Doublet Combinations In Patients With Epithelial Ovarian Or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Gynecologic Oncology Group
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer
A Pilot Study Assessing Patterns of Response or Resistance to Preoperative Dose Dense Docetaxel in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer
A Pilot Study Assessing Patterns of Response or Resistance to Preoperative Dose Dense Docetaxel in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
Phase I-II Study of Denileukin Diftitox (ONTAK®) in Patients With Advanced Refractory Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
Phase I-II Study of Denileukin Diftitox (ONTAK®) in Patients With Advanced Refractory Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Reactions to Disease Risk Information
Participant Reactions to Disease Risk Information
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Reactions to Disease Risk Information
Participant Reactions to Disease Risk Information
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
Phase II Study of Single-Agent Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous, Papillary Serous Endometrial or Fallopian Tube Cancer Who Have Recurred After Prior Therapy With Maintenance Avastin
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
Phase II Study of Single-Agent Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous, Papillary Serous Endometrial or Fallopian Tube Cancer Who Have Recurred After Prior Therapy With Maintenance Avastin
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
Phase II Study of Single-Agent Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous, Papillary Serous Endometrial or Fallopian Tube Cancer Who Have Recurred After Prior Therapy With Maintenance Avastin
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
Phase II Study of Single-Agent Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous, Papillary Serous Endometrial or Fallopian Tube Cancer Who Have Recurred After Prior Therapy With Maintenance Avastin
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
Phase II Study of Single-Agent Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous, Papillary Serous Endometrial or Fallopian Tube Cancer Who Have Recurred After Prior Therapy With Maintenance Avastin
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
Phase II Study of Single-Agent Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous, Papillary Serous Endometrial or Fallopian Tube Cancer Who Have Recurred After Prior Therapy With Maintenance Avastin
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated:  12/31/1969
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated: 12/31/1969
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated:  12/31/1969
Karmanos Cancer Center
mi
from
Detroit, MI
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated: 12/31/1969
Karmanos Cancer Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center, Einstein Cancer Center
mi
from
New York, NY
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center, Einstein Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated:  12/31/1969
University of Kansas Cancer Center
mi
from
Westwood, KA
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated: 12/31/1969
University of Kansas Cancer Center
mi
from
Westwood, KA
Click here to add this to my saved trials
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated:  12/31/1969
MidAmerica Division,Inc
mi
from
Kansas City, MO
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated: 12/31/1969
MidAmerica Division,Inc
mi
from
Kansas City, MO
Click here to add this to my saved trials
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Presbyterian Cancer Center Dallas
mi
from
Dallas, TX
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Presbyterian Cancer Center Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated:  12/31/1969
Oncology Hematology Care
mi
from
Cincinnati, OH
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated: 12/31/1969
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated:  12/31/1969
Valley Hospital
mi
from
Paramus, NJ
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Status: Enrolling
Updated: 12/31/1969
Valley Hospital
mi
from
Paramus, NJ
Click here to add this to my saved trials
Study to Estimate Radiation Doses and Cancer Risks From Radioactive Fallout From the Trinity Nuclear Test
Study to Estimate Radiation Doses and Cancer Risks From Radioactive Fallout From the Trinity Nuclear Test
Status: Enrolling
Updated:  12/31/1969
University of New Mexico
mi
from
Albuquerque, NM
Study to Estimate Radiation Doses and Cancer Risks From Radioactive Fallout From the Trinity Nuclear Test
Study to Estimate Radiation Doses and Cancer Risks From Radioactive Fallout From the Trinity Nuclear Test
Status: Enrolling
Updated: 12/31/1969
University of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery
Intraoperative Pancreatic Cancer Detection Using Multimodality Molecular Imaging
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery
Intraoperative Pancreatic Cancer Detection Using Multimodality Molecular Imaging
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated:  12/31/1969
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated: 12/31/1969
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Click here to add this to my saved trials
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Monmouth
mi
from
Middletown, NJ
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Monmouth
mi
from
Middletown, NJ
Click here to add this to my saved trials
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Westchester
mi
from
Harrison, NY
A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Westchester
mi
from
Harrison, NY
Click here to add this to my saved trials
Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway
Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway: A Single-Blinded, Randomized, Controlled Study
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway
Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway: A Single-Blinded, Randomized, Controlled Study
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Early Life Exposures in Agriculture
Early Life Exposures in Agriculture
Status: Enrolling
Updated:  12/31/1969
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Early Life Exposures in Agriculture
Early Life Exposures in Agriculture
Status: Enrolling
Updated: 12/31/1969
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Click here to add this to my saved trials
Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer
Plasma Tumor DNA and Pathologic Complete Response in Early-Stage, High-Risk Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer
Plasma Tumor DNA and Pathologic Complete Response in Early-Stage, High-Risk Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
Status: Enrolling
Updated:  12/31/1969
NYU Perlmutter Cancer Center
mi
from
New York, NY
A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
Status: Enrolling
Updated: 12/31/1969
NYU Perlmutter Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center Clinical Trials Office
mi
from
New York, NY
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center Clinical Trials Office
mi
from
New York, NY
Click here to add this to my saved trials
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering Cancer Center: Rockefeller Outpatient Pavillion
mi
from
New York, NY
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Center: Rockefeller Outpatient Pavillion
mi
from
New York, NY
Click here to add this to my saved trials
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS
Status: Enrolling
Updated:  12/31/1969
University Hospitals of Cleveland Medical Center
mi
from
Cleveland, OH
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS
Status: Enrolling
Updated: 12/31/1969
University Hospitals of Cleveland Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center Westchester
mi
from
Harrison, NY
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center Westchester
mi
from
Harrison, NY
Click here to add this to my saved trials
Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer
Preliminary Study of Endometrial Hyperplasia: Groundwork for a Study to Define an Optimal Classification of Endometrial Carcinoma Precursors
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Northwest
mi
from
Hillsboro, OR
Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer
Preliminary Study of Endometrial Hyperplasia: Groundwork for a Study to Define an Optimal Classification of Endometrial Carcinoma Precursors
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Northwest
mi
from
Hillsboro, OR
Click here to add this to my saved trials
Biobehavioral Effects of Emotional Expression in Cancer
Biobehavioral Effects of Emotional Expression in Cancer
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Biobehavioral Effects of Emotional Expression in Cancer
Biobehavioral Effects of Emotional Expression in Cancer
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Breast Cancer, Breast Disease, and Pesticides
A Study of Breast Cancer, Breast Disease, Mammographic Density and Pesticides Among a Population From Triana, Alabama
Status: Enrolling
Updated:  12/31/1969
University of Alabama
mi
from
Birmingham, AL
Breast Cancer, Breast Disease, and Pesticides
A Study of Breast Cancer, Breast Disease, Mammographic Density and Pesticides Among a Population From Triana, Alabama
Status: Enrolling
Updated: 12/31/1969
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Proton Therapy for Early Stage Breast Cancer
Phase II Trial of Lumpectomy and Partial Breast Proton Therapy for Early Stage Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Loma Linda University Medical Center / James M. Slater MD Proton Treatment Center / Department of Radiation Medicine / 11234 Anderson St.
mi
from
Loma Linda, CA
Proton Therapy for Early Stage Breast Cancer
Phase II Trial of Lumpectomy and Partial Breast Proton Therapy for Early Stage Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Loma Linda University Medical Center / James M. Slater MD Proton Treatment Center / Department of Radiation Medicine / 11234 Anderson St.
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts
Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts
Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers
A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of Relapse
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers
A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of Relapse
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Efficacy of Ginseng for Patients on Regorafenib
A Randomized Phase II Trial to Evaluate the Efficacy of Supportive Therapy With Ginseng for Patients on Treatment With Regorafenib
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Center at Wake Forest Baptist
mi
from
Winston-Salem, NC
Efficacy of Ginseng for Patients on Regorafenib
A Randomized Phase II Trial to Evaluate the Efficacy of Supportive Therapy With Ginseng for Patients on Treatment With Regorafenib
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Center at Wake Forest Baptist
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Efficacy of Ginseng for Patients on Regorafenib
A Randomized Phase II Trial to Evaluate the Efficacy of Supportive Therapy With Ginseng for Patients on Treatment With Regorafenib
Status: Enrolling
Updated:  12/31/1969
Indiana Univeristy Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Efficacy of Ginseng for Patients on Regorafenib
A Randomized Phase II Trial to Evaluate the Efficacy of Supportive Therapy With Ginseng for Patients on Treatment With Regorafenib
Status: Enrolling
Updated: 12/31/1969
Indiana Univeristy Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials